Publications in OpenAlex of which a co-author is affiliated to this organization
All publications | By field | By subfield
All publications [Next]
| Title | DOI |
|---|---|
| https://doi.org/10.2217/ebo.13.197 | Considerations of practice guidelines and recommendations |
| https://doi.org/10.1177/0019556117750911 | Book review: T.C.A. Raghavan, The People Next Door: The Curious History of India’s Relations with Pakistan |
| https://doi.org/10.2217/ebo.12.91 | VEGF receptor inhibitors |
| https://doi.org/10.1200/jco.2016.34.15_suppl.e20655 | Access to biomarker testing in patients with advanced non-small cell lung cancer. |
| https://doi.org/10.1200/jco.2016.34.15_suppl.9094 | Access to specialist care and treatment in patients with advanced non-small cell lung cancer. |
| https://doi.org/10.1016/j.jtho.2018.11.004 | Indeed, Nuance Matters |
| https://doi.org/10.1016/j.jtho.2019.08.243 | IBS22.02 JTO Workshop: The Life Cycle of a Manuscript |
| https://doi.org/10.1016/j.jtho.2019.08.2489 | YI01.03 Making the Most of WCLC: A Guide for First Time Attendees |
| https://doi.org/10.1016/j.jtho.2019.09.023 | OA01.09 Comparing Regional Results from the IASLC Global Survey on Molecular Testing in Lung Cancer |
| https://doi.org/10.1016/j.jtho.2019.09.091 | O.04 Results from the IASLC Global Survey on Molecular Testing in Lung Cancer |
| https://doi.org/10.1158/1557-3265.covid-19-po-071 | Abstract PO-071: Collaborating to share evidence-based COVID-19 information across lung cancer patient advocacy groups |
| https://doi.org/10.1158/1557-3265.covid-19-po-074 | Abstract PO-074: Patient concerns during the COVID-19 pandemic: Lessons from the lung cancer community |
| https://doi.org/10.1016/j.canep.2021.101884 | Call for papers: Special supplement – Tobacco cessation after a cancer diagnosis |
| https://doi.org/10.3233/acs-1998-8103 | Letter from the Irish Association of Speech and Language Therapists |
| https://doi.org/10.3233/acs-2008-16102 | Letter from Irish Association of Speech and Language Therapists |
| https://doi.org/10.1002/cncy.22081 | Issue Information |
| https://doi.org/10.1002/jcb.29829 | Cover Image, Volume 121, Number 8‐9, August 2020 |
| https://doi.org/10.7149/opa.55.4.5542 | SEDOPTICA Newsletter |
| https://doi.org/10.1016/j.jtho.2022.09.079 | PP01.53 Pathologic Response Assessment Tool – Architecting a Cloud-Based Tool to Streamline Logistics for Shipping, Tracking, Scoring, and Reporting |
| https://doi.org/10.1016/j.jtho.2022.09.065 | PP01.39 Infrastructure for Interobserver Variability Assessment of Pathologic Response (PR), in Surgical Resection Specimens Following Neoadjuvant Immune Check Point Inhibitor (ICI) Therapies in Early Stage NSCLC |
| https://doi.org/10.1093/ecco-jcc/jjad212.0555 | P425 Clinical Characteristics of Steroid-Dependent Ulcerative Colitis Patients after Acute Severe Ulcerative Colitis Treatment in East Asia and Australia/New Zealand: AOCC and ANZIBDC collaboration study |
| https://doi.org/10.1158/1078-0432.c.7181344.v1 | Data from Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial |
| https://doi.org/10.1200/jco.2024.42.16_suppl.8036 | Prospective “common arm” comparison of US SWOG S0424 and Japanese JME studies in early-stage non-small cell lung cancer (NSCLC): Survival differences in the context of race, gender and smoking. |
| https://doi.org/10.1016/j.annonc.2024.08.2209 | 204P Assessing biomarker testing awareness among patients and caregivers in NSCLC through an interdisciplinary global survey |
| https://doi.org/10.1016/j.jtho.2024.09.246 | P1.01A.01 The INHERIT Study - Investigating Hereditary Risk in Thoracic Cancers (NCT05587439) |
| https://doi.org/10.1016/j.jtho.2024.09.1436 | Why and When Do We Invasively Restage After Neoadjuvant Chemoimmunotherapy? |
| https://doi.org/10.1016/j.jtocrr.2025.100816 | Biomarker Testing and Patterns of Treatment in Patients with NSCLC: An International Association for The Study of Lung Cancer Analysis of American Society of Clinical Oncology CancerLinQ Discovery Data |
| https://doi.org/10.1016/s1556-0864(25)00296-5 | 101P: European results from the 2024 International Association for the Study of Lung Cancer (IASLC) global survey on biomarker testing |
| https://doi.org/10.1164/ajrccm.2025.211.abstracts.a5016 | Cancer Outcomes in the Watch the Spot Trial: A Pragmatic Clinical Trial of Less Compared With More Intensive Strategies for Active Surveillance of Patients With Small Pulmonary Nodules |
| https://doi.org/10.1158/1078-0432.ccr-24-3658 | Elevated ctDNA Tumor Fraction Is Associated with Improved Mutation Detection but Worse Overall Survival in Advanced Non–Small Cell Lung Cancer: A Lung-MAP Study |
| https://doi.org/10.1164/ajrccm.2025.211.abstracts.a7992 | Cancer Outcomes in the Watch the Spot Trial: A Pragmatic Clinical Trial of Less Compared to More Intensive Strategies for Active Surveillance of Patients With Small Pulmonary Nodules |
| https://doi.org/10.1016/j.jtho.2025.09.069 | OA12.01 IASLC Mesothelioma Staging Project: Impact of Molecular Alterations on Survival in a Cohort From 9th Edition Database |
| https://doi.org/10.1016/j.jtho.2025.09.1182 | PT2.17.04 First Assessment of IASLC Inclusive Practices and Challenges: Results From the Diversity, Equity, and Inclusion Survey |
| https://doi.org/10.1016/j.jtho.2025.09.065 | OA11.01 Impact of Smoking Status on the Prognosis of Lung Cancer in the IASLC Ninth Edition TNM Classification Database |
| https://doi.org/10.1016/j.jtho.2025.09.1116 | PT1.03.04 VIKTOR - the Virtual International Knowledgebase for Thoracic Oncology Research of the IASLC |
| https://doi.org/10.1016/j.jtho.2025.09.058 | OA09.01 Machine Learning Assessment of Pathologic Response in Lung Resections After Neoadjuvant Therapy - IASLC MPR Project |
| https://doi.org/10.1016/j.jtho.2025.09.409 | P1.17.24 Mixed Methods IASLC Global Survey and Provider Interview Study of Us NSCLC Biomarker Testing Practices and Clinical Processes |
| https://doi.org/10.1016/j.jtho.2025.09.066 | OA11.02 Molecular Alterations and Survival: Analyses from IASLC 9th Edition Staging Database |
| https://doi.org/10.1016/j.jtho.2025.09.148 | MA07.01 A Grading System for Invasive Squamous Cell Carcinoma of the Lung: A Multi-Institutional Study by the IASLC Pathology Committee |
| https://doi.org/10.1016/j.jtho.2025.09.092 | OA18.01 Improving Lung Cancer Outcomes Through Policy a Global Perspective on Risk Reduction, Early Detection, Care and Survivorship |
| https://doi.org/10.1016/j.jtho.2025.10.006 | Corrigendum to “The International Association for the Study of Lung Cancer Staging Project: The Impact of Common Molecular Alterations on Overall Survival in NSCLC in Initial Analyses of the IASLC Ninth Edition Staging Database. [Journal of Thoracic Oncology Vol. 20 No. 10: 1423–1440]” |
| https://doi.org/10.1016/j.annonc.2025.09.081 | LBA69 SKYSCRAPER-03: Phase III, open-label, randomised study of atezolizumab (atezo) + tiragolumab (tira) vs durvalumab (durva) in locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC) after platinum-based concurrent chemoradiation (cCRT) |
| https://doi.org/10.1016/j.jtocrr.2025.100944 | Tolerance and Resistance to Targeted Therapy in NSCLC: Emerging Concepts and Strategies |
| https://doi.org/10.1007/s00280-025-04844-y | A phase 1 study of orally administered 5-fluoro-2’-deoxycytidine with tetrahydrouridine in patients with refractory solid tumors |
| https://doi.org/10.1016/j.jtho.2026.103681 | The International Association for the Study of Lung Cancer Pleural Mesothelioma Staging Project: Impact of Common Molecular Alterations and PD-L1 Expression on Overall Survival in a Select Cohort from the IASLC 9th Edition Staging Database |
| https://doi.org/10.1016/j.esmoop.2026.106815 | 500MO PD-L1 Blueprint AI: Validation of an AI-assisted PD-L1 scoring algorithm against original Blueprint study data |
| https://doi.org/10.1158/1538-7445.am2026-6353 | Abstract 6353: Age-related differences in lung cancer patients’ and caregivers' perceptions and challenges: 2025 |